Biopharma and healthcare group Chiesi Farmaceutici S.p.A. is to acquire the 2015-established Amryt Pharma Plc. in an all-cash transaction at $14.50 per American Depositary Share (ADS). Each ADS ...

UK-based specialist Amryt Pharma is looking to expand in 2018 after acquiring two rare disease treatments. A relative newcomer to the niche rare disease market, Amryt Pharma was founded by former ...

Turning now to Elfabrio. Throughout 2024, our commercial partner, Chiesi Global Rare Diseases, continued to increase its focus on Elfabrio and invest heavily in its medical and commercial program.

Despite a terrific game and a good team win for Iowa State basketball over Cincinnati in the second round of the Big 12 Tournament on Wednesday, starting guard Tamin Lipsey went to the locker room ...

Amryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®) DUBLIN, Ireland, and Boston MA, March 31, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global ...

McAdams-DeMarco has received speaking fees from Chiesi. Segev has served as a consultant for and/or received speaking fees from pharmaceutical and healthcare companies AstraZeneca, Behring ...

Yet in the past few years, B Corp has garnered controversy over awarding its logo to corporations such as Nestlé-owned Nespresso, the pharmaceutical Chiesi Group which is part of an industry ...

Rivian's R2 SUV, which is expected to challenge Tesla's Model Y, will launch early next year.

Jazz Pharmaceuticals is set to acquire Chimerix, a biotechnology company developing oncology therapies and others for a deal size of approximately $935m set to close in Q2 2025. The acquisition adds ...

Chiesi USA of Cary and its European partner Holostem Terapie Avanzate have received Orphan Drug Designation from the U.S. Food and Drug Administration for an investigational cell-based therapy for a ...